EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression

Michael C Brumm, Andrew Siderowf, Tanya Simuni, Elliot Burghardt, Seung Ho Choi, Chelsea Caspell-Garcia, Lana M Chahine, Brit Mollenhauer, Tatiana Foroud, Douglas Galasko, Kalpana Merchant, Vanessa Arnedo und 9 weitere

Journal of Parkinson’s Disease · 26.07.2023 · 13 (6) · 899-916

DOI: 10.3233/jpd-223433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 12.07.2023. Verfasst von Michael C Brumm und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Primary Dysautonomias. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge.

Objective

To assess the frequency and baseline predictors of progression to clinically relevant motor and non-motor PD milestones.

Methods

Using data from the Parkinson’s Progression Markers Initiative (PPMI) de novo PD cohort, we monitored 25 milestones across six domains (“walking and balance”; “motor complications”; “cognition”; “autonomic dysfunction”; “functional dependence”; “activities of daily living”). Milestones were intended to be severe enough to reflect meaningful disability. We assessed the proportion of participants reaching any milestone; evaluated which occurred most frequently; and conducted a time-to-first-event analysis exploring whether baseline characteristics were associated with progression.

Results

Half of participants reached at least one milestone within five years. Milestones within the cognitive, functional dependence, and autonomic dysfunction domains were reached most often. Among participants who reached a milestone at an annual follow-up visit and remained active in the study, 82% continued to meet criteria for any milestone at one or more subsequent annual visits and 55% did so at the next annual visit. In multivariable analysis, baseline features predicting faster time to reaching a milestone included age ( p < 0.0001), greater MDS-UPDRS total scores ( p < 0.0001), higher GDS-15 depression scores ( p = 0.0341), lower dopamine transporter binding ( p = 0.0043), and lower CSF total α-synuclein levels ( p = 0.0030). Symptomatic treatment was not significantly associated with reaching a milestone ( p = 0.1639).

Conclusion

Clinically relevant milestones occur frequently, even in early PD. Milestones were significantly associated with baseline clinical and biological markers, but not with symptomatic treatment. Further studies are necessary to validate these results, further assess the stability of milestones, and explore translating them into an outcome measure suitable for observational and therapeutic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseasePrimary DysautonomiasHumansBiomarkersCognitionDisease Progression

Stichwörter der Autor:innen

Parkinson’s diseaseclinical trials as topicdisease progressionoutcome measures

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.
  • Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Department of Neurology, University Medical Center Goettingen, Goettingen, Germany.
  • Paracelsus-Elena Klinik, Kassel, Germany.

Zitieren

APA

Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., Merchant, K., Arnedo, V., Hutten, S. J., O'Grady, A. N., Poston, K. L., Tanner, C. M., Weintraub, D., Kieburtz, K., Marek, K., …, & Parkinson’s Progression Markers Initiative (2023). Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. Journal of Parkinson’s Disease, 13(6), 899-916. https://doi.org/10.3233/jpd-223433

Vancouver

Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, et al. Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. Journal of Parkinson’s Disease. 2023;13(6):899-916. doi:10.3233/jpd-223433

BibTeX
@article{Brumm2023,
  author = {Brumm, Michael C and Siderowf, Andrew and Simuni, Tanya and Burghardt, Elliot and Choi, Seung Ho and Caspell-Garcia, Chelsea and Chahine, Lana M and Mollenhauer, Brit and Foroud, Tatiana and Galasko, Douglas and Merchant, Kalpana and Arnedo, Vanessa and Hutten, Samantha J and O'Grady, Alyssa N and Poston, Kathleen L and Tanner, Caroline M and Weintraub, Daniel and Kieburtz, Karl and Marek, Kenneth and Coffey, Christopher S and Parkinson’s Progression Markers Initiative, Parkinson’s Progression Markers Initiative},
  title = {Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression},
  journal = {Journal of Parkinson’s Disease},
  year = {2023},
  volume = {13},
  number = {6},
  pages = {899--916},
  doi = {10.3233/jpd-223433}
}
Kostenlos starten →